Case Study: Inside Kinaset’s $103M Oversubscribed Series B: Strategy, Syndicate and Execution
Tue, May 12
|
10:15 AM - 10:40 AM
Picasso 4&5
Session details:
- Positioning frevecitinib and the broader company story to resonate with investors
- Bringing together a mix of new and existing investors, and why that mattered
- Lessons learned for biotech leaders preparing for late-stage private financing
